Idexx CEO Takes Medical Leave After Serious Cycling Accident
(Bloomberg) -- Idexx Laboratories Inc. Chief Executive Officer Jonathan Ayers is taking a medical leave of absence following what the company said was a “serious bicycling accident” on June 27.
Idexx's executive vice president Jay Mazelsky will serve as interim CEO, the company said in a statement. Chief Financial Officer Brian McKeon and Larry Kingsley, the independent lead director of Idexx's board, will also provide support.
“Jon has expressed his confidence in Jay, Brian and Idexx's talented leadership team,” Kingsley said.
Ayers, 63, has served as CEO since 2002. In a 2018 interview posted on YouTube, Ayers said he had taken up cycling again at age 54, and had done some amateur racing. In the online interview, he described the sport as a way to provide focus and a break from his intense role as a business leader.
“Cycling is like a refuge. You're just another cyclist,” Ayers said in the interview. “It's a different way of living. I'm not the CEO, I'm just a cyclist.” He said he trains about 10 hours a week.
The Westbrook, Maine-based life-science equipment company declined to provide further comment on the nature of Ayers's injuries or a timeline for his return. The company makes many commonly used tests for veterinary medicine, as well as testing for water and milk. It has a market value of about $24 billion.
Idexx has gained 50% this year to date under Ayers, including a 1.1% gain Monday as U.S. stocks touched all-time highs.
To contact the reporter on this story: Myah Ward in New York at mward174@bloomberg.net
To contact the editors responsible for this story: Drew Armstrong at darmstrong17@bloomberg.net, Timothy Annett
©2019 Bloomberg L.P.
-
The Economic Imperative: Analysing The Material Driving Force Behind India-Canada Strategic Reset
This economic complementarity is further reinforced by deep institutional investment ties and talent mobility, which form the bedrock of the bilateral framework.
-
Medicine Pricing: Where Must Profit Stop?
India must confront excessive margins, hidden incentives and regulatory gaps that threaten the integrity of medicine.
-
Why Amazon And Flipkart Are Struggling To Beat Meesho In India's Smaller Cities
With 274 million users and lowest-cost logistics, Meesho is defending its value commerce crown against giants like Amazon and Flipkart.
-
High US Salaries, No Green Card Certainty: The Financial Calculation Facing Indian H-1B Families
The suspension of PERM processing at eight technology employers does not cancel existing H-1B visas. What it does is force a question many Indian families have been avoiding: is the US salary worth tying your career and family plans to one employer?
-
Swiggy vs Eternal: Food Delivery's Two Rivals Are No Longer In The Same Race
Eternal is building a private AI assistant, dark.ai. Swiggy is still working out how to make Instamart pay, with an operating loss of Rs 895 crore in the July-September quarter while Blinkit stayed profitable.
-
Where You Live Shapes How You Get To Work | The Reason Why
Two-wheelers are the most popular way to get to work in India, accounting for nearly 43% of workplace commutes.
-
Unhedged Position: Can India See An Indonesia-Style Time Correction?
The Nifty is trading below levels it first clocked in 2024. Is there, then, as I have suggested in the headline, potential that the current time correction drags on painfully for the next three-five, even ten years?
-
Navigating Friction And Energy Realities: An Analysis Of Marco Rubio's October Visit To India
Occurring at a critical juncture marked by stalled trade negotiations and escalating geopolitical pressures over global energy supplies, the visit offers a profound window into modern US-India relations.
-
India Exports Capital. Why Not Export Trusteeship?
The big question, then, is whether India can build an institution that global borrowers, investors, banks, and lawyers can trust, even without an Indian connection.
-
France's Economy & Politics Are In Crisis | The Reason Why
Let's look at how the French economy and politics evolved under Nicolas Sarkozy, Franois Hollande and Emmanuel Macron.